CAS 1644545-52-7

Vorasidenib

CAS: 1644545-52-7

Fórmula: C₁₄H₁₃ClF₆N₆

Pureza: 98%

Forma y color: Solid

Peso molecular: 414.7366

Ref: IN-DA01EOEI

Vorasidenib

CAS: 1644545-52-7

Vorasidenib

Fórmula: C₁₄H₁₃ClF₆N₆

Pureza: ≥98%

Peso molecular: 414.74

Ref: 54-BUP03643

Vorasidenib

CAS: 1644545-52-7

6-(6-Chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoropropan-2-yl)-1,3,5-triazine-2,4-diamine

Fórmula: C₁₄H₁₃ClF₆N₆

Pureza: 99%

Peso molecular: 414.74

Ref: IN-DG00777198

Vorasidenib

CAS: 1644545-52-7

Vorasidenib (PVM/MA) is an inhibitor of mutant isocitrate dehydrogenase (IDH; IC50s = 31.9 and 31.7 nM for IDH1R132H and IDH2R140Q, respectively)

Fórmula: C₁₄H₁₃ClF₆N₆

Pureza: 98.28% - 99.57%

Forma y color: Solid

Peso molecular: 414.74

Ref: TM-T7307

Vorasidenib

CAS: 1644545-52-7

Vorasidenib is a drug that has been approved for the treatment of adults with newly diagnosed glioblastoma. It is currently being investigated in preoperative settings, to see if it can reduce or eliminate the need for radiation therapy. Vorasidenib is an anti-angiogenic drug that blocks both vascular endothelial growth factor and platelet-derived growth factor receptors, which are key components of tumor angiogenesis. The drug has been shown to prolong survival in patients with malignant brain tumors and has few serious side effects. A multicenter phase II study showed a response rate of about 20% in patients with newly diagnosed gliomas who were given vorasidenib. Pharmacokinetic studies have demonstrated that vorasidenib crosses the blood-brain barrier and penetrates into the tumor cells at levels higher than other drugs used to treat gliomas.

Fórmula: C₁₄H₁₃ClF₆N₆

Pureza: Min. 95%

Peso molecular: 414.74 g/mol

Ref: 3D-UQC54552

Vorasidenib

CAS: 1644545-52-7

Fórmula: C₁₄H₁₃ClF₆N₆

Peso molecular: 414.74

Ref: 4Z-V-115001